帕金宁控释片治疗帕金森病疗效的研究

Clinical Effects of Controlled-release Sinemet on Parkinson's Disease

应用帕金宁控释片治疗１４例原发性帕金森病和１例锰中毒帕金森综合征。未用过多巴类药物治疗的６例中，显效１例，有效５例。已用过美多巴治疗者９例，均伴剂未现象，其中２例伴峰值期运动障碍，改用帕金宁控释片后，每日剂量较美多巴标准片增加２６．７％，对上述现象均有效。早晨服用帕金宁控释片后由于缓释关系较美多巴片起效慢，故建议早晨加服帕金宁标准片或美多巴。

Fourteen patients with idiopathic Parkinson's disease and one patient with secondary parkinsonism were treated with controlled-release formulation of carbidopa-levodopa(Sinemet CR).For 6 patients who had never taken levodopa before,siguificant improvement and modest improvement were made after Sinemet CR therapy.For 9 patients with some complications of wearing -off(9 cases) and peak-dose dyskinesia(2 cases),a modest increase in daily“on”time and an improvement in dyskinesia were made after the transition from standard Madopar to Sinemet CR.Bioavailability of Sinemet CR is less and slower than that of standard Sinemet or Madopar,so total daily levodopa dose is increased by 26.7%to achieve a comparable effect. While taking Sinemet CR in the morning,patients should add standard Sinemet or Madopar to overcome the controlled-release form's slower onset of therapeutic effect.Gastrointestinal adverse effect has been observed in some patients.